FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489465352> ?p ?o ?g. }

• W1489465352 abstract "Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of pluripotent hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the molecular and cellular basis of human malignancies. It has provided an excellent example of how a specific molecular abnormality can be targeted therapeutically to transform a lifethreatening malignancy into a chronic disease. The study of CML has been characterized by a number of ‘firsts’. CML was the first malignancy to be: (i) associated with a specific chromosomal abnormality, (ii) associated with a specific molecular alteration (BCR-ABL) and (iii) successfully treated with a specifically designed targeted therapeutic agent. As such it seems natural that CML should be the first human malignancy in which a complete medical cure is achieved through the eradication of cancer stem cells. This should be realizable through combining the specific targeting of BCR-ABL and CML stem cells. Once this has been achieved, the challenge will be to successfully transfer the lessons learned from this relatively simple and well-characterized model system to the eradication of cancer stem cells in more complex malignancies. The treatment of CML has changed dramatically following the introduction into the clinic of the tyrosine kinase inhibitor (TKI) imatinib mesylate and second generation TKIs. These agents directly target the BCR-ABL oncoprotein product of the constitutively active BCRABL tyrosine kinase. The specific targeting of BCR-ABL induces durable clinical remission in a high proportion of chronic phase CML (CP-CML) subjects (5 year survival of 89%) (Druker et al, 2006). Although a major molecular response (defined as a 3-log reduction in BCR-ABL mutant allele burden) is obtained in many CP-CML patients, only a small number attain PCR negativity as determined by the absence of residual BCR-ABL transcripts (Hughes et al, 2003). This is because TKI therapy does not specifically target or eliminate leukemia stem cells (LSCs). Indeed TKI therapy alone is unlikely to ever be curative, as following treatment with TKIs LSCs persist in bone marrow (BM) stem cell niches where they harbor the potential for relapse. The emergence of resistance to TKI monotherapy" @default.
• W1489465352 created "2016-06-24" @default.
• W1489465352 creator A5012922730 @default.
• W1489465352 creator A5046233977 @default.
• W1489465352 date "2011-12-14" @default.
• W1489465352 modified "2023-10-02" @default.
• W1489465352 title "Targeting the Chronic Myeloid Leukemia Stem Cell: A Paradigm for the Curative Treatment of Human Malignancies" @default.
• W1489465352 cites W120597284 @default.
• W1489465352 cites W1592032137 @default.
• W1489465352 cites W1619157245 @default.
• W1489465352 cites W1965323879 @default.
• W1489465352 cites W1965553215 @default.
• W1489465352 cites W1967920366 @default.
• W1489465352 cites W1968655578 @default.
• W1489465352 cites W1969228079 @default.
• W1489465352 cites W1972012172 @default.
• W1489465352 cites W1973901560 @default.
• W1489465352 cites W1975595356 @default.
• W1489465352 cites W1975748957 @default.
• W1489465352 cites W1976409591 @default.
• W1489465352 cites W1980473329 @default.
• W1489465352 cites W1981083415 @default.
• W1489465352 cites W1983399256 @default.
• W1489465352 cites W1984197873 @default.
• W1489465352 cites W1987239635 @default.
• W1489465352 cites W1990020715 @default.
• W1489465352 cites W1994072538 @default.
• W1489465352 cites W1994309500 @default.
• W1489465352 cites W1995456504 @default.
• W1489465352 cites W1995670055 @default.
• W1489465352 cites W1995940184 @default.
• W1489465352 cites W1996346809 @default.
• W1489465352 cites W1996661303 @default.
• W1489465352 cites W1997187693 @default.
• W1489465352 cites W1999614615 @default.
• W1489465352 cites W2004821524 @default.
• W1489465352 cites W2004999590 @default.
• W1489465352 cites W2007633189 @default.
• W1489465352 cites W2008188428 @default.
• W1489465352 cites W2008267412 @default.
• W1489465352 cites W2011474502 @default.
• W1489465352 cites W2012153991 @default.
• W1489465352 cites W2012962381 @default.
• W1489465352 cites W2014316424 @default.
• W1489465352 cites W2015616444 @default.
• W1489465352 cites W2015735402 @default.
• W1489465352 cites W2016086822 @default.
• W1489465352 cites W2016809033 @default.
• W1489465352 cites W2017728128 @default.
• W1489465352 cites W2018279800 @default.
• W1489465352 cites W2021050536 @default.
• W1489465352 cites W2024290860 @default.
• W1489465352 cites W2026359801 @default.
• W1489465352 cites W2026389791 @default.
• W1489465352 cites W2028085190 @default.
• W1489465352 cites W2028959752 @default.
• W1489465352 cites W2029303104 @default.
• W1489465352 cites W2029638992 @default.
• W1489465352 cites W2031313479 @default.
• W1489465352 cites W2032224060 @default.
• W1489465352 cites W2033836017 @default.
• W1489465352 cites W2036267284 @default.
• W1489465352 cites W2036625526 @default.
• W1489465352 cites W2036987278 @default.
• W1489465352 cites W2037837200 @default.
• W1489465352 cites W2040396943 @default.
• W1489465352 cites W2041004587 @default.
• W1489465352 cites W2046697661 @default.
• W1489465352 cites W2046916766 @default.
• W1489465352 cites W2048228382 @default.
• W1489465352 cites W2049228075 @default.
• W1489465352 cites W2050369011 @default.
• W1489465352 cites W2051577500 @default.
• W1489465352 cites W2052927522 @default.
• W1489465352 cites W2054251966 @default.
• W1489465352 cites W2055049504 @default.
• W1489465352 cites W2057718276 @default.
• W1489465352 cites W2061860992 @default.
• W1489465352 cites W2063686290 @default.
• W1489465352 cites W2063700839 @default.
• W1489465352 cites W2064790088 @default.
• W1489465352 cites W2066148382 @default.
• W1489465352 cites W2068834508 @default.
• W1489465352 cites W2069796323 @default.
• W1489465352 cites W2071534620 @default.
• W1489465352 cites W2072008804 @default.
• W1489465352 cites W2074740152 @default.
• W1489465352 cites W2075706560 @default.
• W1489465352 cites W2078904530 @default.
• W1489465352 cites W2079517811 @default.
• W1489465352 cites W2081414779 @default.
• W1489465352 cites W2082469361 @default.
• W1489465352 cites W2082580993 @default.
• W1489465352 cites W2083967825 @default.
• W1489465352 cites W2090004346 @default.
• W1489465352 cites W2091423586 @default.
• W1489465352 cites W2092219259 @default.
• W1489465352 cites W2092606584 @default.
• W1489465352 cites W2094097897 @default.
• W1489465352 cites W2095229706 @default.

• next